Lip cancer

disease
On this page

Also known as cancer of lipmalignant Lip neoplasmmalignant Lip tumormalignant Lip tumourmalignant neoplasm of Lipmalignant neoplasm of lip, inner aspectmalignant neoplasm of lip, unspecifiedmalignant neoplasm of lip, unspecified, inner aspectmalignant neoplasm of lip, unspecified, vermilion bordermalignant neoplasm of oral aspect of lip, not specified whether upper or lowermalignant neoplasm of the Lipmalignant tumor of commissure of lipmalignant tumor of labial commissuremalignant tumor of Lipmalignant tumor of the Lipmalignant tumour of commissure of lipmalignant tumour of labial mucosamalignant tumour of Lipmalignant tumour of lower labial mucosa

Summary

Lip cancer (MONDO:0006834) is a cancer and 9 clinical trials. Top therapeutic interventions include cisplatin and trastuzumab botidotin. A subtype of oral cavity cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namelip cancer
Mondo IDMONDO:0006834
EFOEFO:1001019
MeSHD008048
DOIDDOID:8564
ICD-10-CMC00
ICD-11304997495
NCITC7485
SNOMED CT187622006
UMLSC0153340
MedGen57548
GARD0027767
MedDRA10007089
Anatomy (UBERON)UBERON:0001833
Is cancer (heuristic)yes

Also known as: cancer of lip · lip cancer · malignant Lip neoplasm · malignant lip neoplasm · malignant Lip tumor · malignant Lip tumour · malignant neoplasm of Lip · malignant neoplasm of lip · malignant neoplasm of lip, inner aspect · malignant neoplasm of lip, unspecified · malignant neoplasm of lip, unspecified, inner aspect · malignant neoplasm of lip, unspecified, vermilion border · malignant neoplasm of oral aspect of lip, not specified whether upper or lower · malignant neoplasm of the Lip · malignant tumor of commissure of lip · malignant tumor of labial commissure · malignant tumor of Lip · malignant tumor of lip · malignant tumor of the Lip · malignant tumour of commissure of lip (+5 more)

Disease family

This is a subtype of oral cavity cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderdigestive system canceroral cavity cancerlip cancer

Related subtypes (10): soft palate cancer, tongue cancer, cheek mucosa cancer, salivary gland cancer, retromolar area cancer, hard palate cancer, vestibule of mouth cancer, gingival cancer, oral cavity carcinoma, oral rhabdomyosarcoma

Subtypes (3): upper lip cancer, lower lip cancer, carcinoma of lip

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified7
PHASE21
PHASE1/PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03174275PHASE2ACTIVE_NOT_RECRUITINGCarboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
NCT03602079PHASE1/PHASE2COMPLETEDStudy of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
NCT00568490Not specifiedRECRUITINGIdentification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
NCT02012699Not specifiedRECRUITINGIntegrated Cancer Repository for Cancer Research
NCT05837221Not specifiedRECRUITINGMicrobiome in Head and Neck Squamous Cell Carcinoma
NCT00186433Not specifiedCOMPLETEDA Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
NCT01084733Not specifiedCOMPLETEDNicotine Levels With Response Rates to Radiation Alone or With Chemo In Head & Neck Cancer
NCT05610293Not specifiedUNKNOWNT1 Squamous Cell Carcinomas of the Lip
NCT07005115Not specifiedCOMPLETEDSerum Lipid Profile and Lip Squamous Cell Carcinoma

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
CISPLATIN41
TRASTUZUMAB BOTIDOTIN21